EMEA-000434-PIP01-08-M06
Key facts
| Invented name |
Volibris
|
| Active substance |
ambrisentan
|
| Therapeutic area |
Cardiovascular diseases
|
| Decision number |
P/0370/2019
|
| PIP number |
EMEA-000434-PIP01-08-M06
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Pulmonary arterial hypertension
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Glaxo Group Limited
Tel. +1 4388998201 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|